LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genome Sequencing of MRSA Infection Predicts Disease Severity

By LabMedica International staff writers
Posted on 24 Apr 2014
Image: The Genome Analyzer IIx (Photo courtesy of Illumina).
Image: The Genome Analyzer IIx (Photo courtesy of Illumina).
Image: The highly toxic methicillin-resistant Staphylococcus aureus (MRSA) strain (top) and less toxic strain (bottom) cultured on a blood agar plate (Photo courtesy of Ruth Massey).
Image: The highly toxic methicillin-resistant Staphylococcus aureus (MRSA) strain (top) and less toxic strain (bottom) cultured on a blood agar plate (Photo courtesy of Ruth Massey).
Bacterial pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), cause disease in part due to toxicity, or the bacterium's ability to damage a host's tissue.

The spread of the antibiotic-resistant pathogen remains a concerning public health problem, especially among doctors trying to determine appropriate treatment options for infected patients.

Microbiologists at the University of Bath (UK) and a team of international scientists used whole genome sequences from 90 MRSA isolates to identify over 100 genetic loci associated with toxicity. Bacterial adhesion to human fibronectin and fibrinogen was assessed and adherent bacteria were calculated by using the crystal violet method and absorbance measured at A595 using a microtiter plate reader. The toxicity of individual isolates was assayed in three ways.

The identification of genetic variation in the clinical isolates was studied using unique index-tagged libraries created for each sample, and up to 12 separate libraries were sequenced in each of eight channels in the Genome Analyzer GAIIx cells (Illumina; San Diego, CA, USA) with 75-base paired-end reads.

The authors found that by using whole genome sequences from 90 MRSA isolates they were able to identify over 100 genetic loci associated with toxicity and despite belonging to the same ST239 clone, the isolates varied greatly in toxicity. Importantly, the highly toxic isolates shared a common genetic signature. By looking for this signature in the MRSA genome, the investigators were able to predict which isolates were the most toxic and thus more likely to cause severe disease when used to infect mice.

Ruth C. Massey, PhD, the lead author of the study, said, “As the cost and speed of genome sequencing decreases, it is becoming increasingly feasible to sequence the genome of an infecting organism. In a clinical setting, sequencing may be useful for deciding the course of MRSA treatment. For example, a clinician may treat a highly toxic infection more aggressively, including prescribing certain antibiotics known to reduce toxin expression. The patient also may be monitored more closely for complications and isolated from others to help control the spread of infection.” The study was published on April 9, 2014, in the journal Genome Research.

Related Links:

University of Bath
Illumina


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more